About Gordian

Gordian Biotechnologies is a privately held biotechnology company developing a portfolio of first-in-class non-covalently bound reversible β-lactamase inhibitors that allow existing antibiotics to be effective against otherwise resistant pathogens. Its  third generation BLI is specifically designed to target Extended spectrum beta-lactamase (ESBL) resistance and render it ineffective.

β‑lactamases are enzymes produced by bacteria that destroy the antibiotic activity of β‑lactam antibiotics, such as penicillin derivatives, cephalosporins, monobactams and carbapenems.  For more information on β‑lactamases and our candidate inhibitors, visit our Research & Development page.

Why Gordian

Gordian is creating clinical value for future patients and shareholder value for our investors.  We are developing a novel class of beta-lactamase inhibitors to tackle the worldwide problem of antibiotic resistance.

Antibiotic resistance is a problem, Gordian is developing a solution.

Gordian - unraveling bacterial resistance.


About us

Gordian is making the existing portfolio of available beta-lactam antibiotics (65% of all antibiotic prescriptions) effective against pathogens that are otherwise resistant. We have an excellent, experienced team, and world-class science.

Read more


Why Us

World class science and an experienced team have come together to develop a pipeline of first-in-class non-covalent reversible inhibitors of beta-lactamase to revitalize existing beta-lactam antibiotics and address antibiotic resistance.